WallStSmart

Merck & Company Inc (MRK)vsPetMed Express Inc (PETS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 34672% more annual revenue ($65.01B vs $186.96M). MRK leads profitability with a 28.1% profit margin vs -34.7%. PETS appears more attractively valued with a PEG of 2.32. MRK earns a higher WallStSmart Score of 59/100 (C).

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9

PETS

Hold

43

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$109.18

$12.70 premium

UndervaluedFair: $96.48Overvalued
PETSUndervalued (+83.0%)

Margin of Safety

+83.0%

Fair Value

$17.51

Current Price

$2.24

$15.27 discount

UndervaluedFair: $17.51Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

PETS2 strengths · Avg: 10.0/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

EPS GrowthGrowth
266.7%10/10

Earnings expanding 266.7% YoY

Areas to Watch

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

PETS4 concerns · Avg: 2.8/10
PEG RatioValuation
2.324/10

Expensive relative to growth rate

Market CapQuality
$48.15M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-100.6%2/10

ROE of -100.6% — below average capital efficiency

Revenue GrowthGrowth
-21.7%2/10

Revenue declined 21.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bull Case : PETS

The strongest argument for PETS centers on Price/Book, EPS Growth.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Bear Case : PETS

The primary concerns for PETS are PEG Ratio, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while PETS is a turnaround play — different risk/reward profiles.

PETS carries more volatility with a beta of 0.78 — expect wider price swings.

MRK is growing revenue faster at 5.0% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (59/100 vs 43/100), backed by strong 28.1% margins. PETS offers better value entry with a 83.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

PetMed Express Inc

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

PetMed Express, Inc., doing business as 1-800-PetMeds, is a pet pharmacy in the United States. The company is headquartered in Delray Beach, Florida.

Want to dig deeper into these stocks?